Melola Discovery

← Melola Discovery

Akses terbuka Jurnal SINTA 1

Serum DNase1, sTNFR1 and sTNFR2 as Risk Factors for Lupus Nephritis in Systemic Lupus Erythematosus Patients

The Indonesian Biomedical Journal · Vol. 16 No. 3 (2024) · hlm. 263–268

DOI
10.18585/inabj.v16i3.3052
ISSN
2085-3297, 2355-9179
Terbit
2024-06-26
Penerbit
Secretariat of The Indonesian Biomedical Journal
Bahasa
en
Lisensi
creativecommons.org/licenses/by-nc/4.0/

Abstrak

BACKGROUND: Early detection and management of lupus nephritis (LN) in systemic lupus erythematosus (SLE) are essential to prevent irreversible kidney damage and improve patient outcomes; therefore, identifying reliable biomarkers to predict LN is paramount. However, there are still relatively few studies examining the potential biomarkers for LN in SLE patients. This study was conducted to investigate serum deoxyribonuclease I (DNase), soluble tumor necrosing factor 1 (sTNFR1) and soluble tumor necrosing factor 2 (sTNFR2) as a risk factor for LN in SLE patients.METHODS: A case-control study involving SLE patients aged 20-60 years was conducted. Blood was withdrawn from each subject for the measurement of serum level of DNase1, sTNFR1, and sTNFR2 that was performed using enzyme-linked immunoassay (ELISA) methods. Data was then analyzed using Chi-Square test and logistic regression tests.RESULTS: A total of 22 patients with LN and 22 without LN were included. The cut-off value for DNase1, sTNFR1, and sTNFR2 were 5.05 ng/mL, 6.52 ng/mL, and 7.02 ng/mL, respectively. The risk factors of LN in SLE patients were the low level of serum DNase1 (aOR=6.64; 95%CI: 1.25-35.29; p=0.026), low level of serum sTNFR1 (aOR=8.12; 95% CI: 1.56-42.10; p=0.013), and low level of serum sTNFR2 (aOR=5.57; 95%CI: 1.03-30.11; p=0.046).CONCLUSION: Serum DNase1 lower than 5.05 ng/mL, sTNFR1 lower than 6.52 ng/mL, and sTNFR2 lower than 7.02 ng/mL were risk factors for lupus nephritis in SLE patients. Hence, serum DNase1, sTNFR1 and sTNFR2 could be used as risk factors predictors for LN in SLE patients.KEYWORDS: DNase1, sTNFR1, sTNFR2, SLE, lupus nephritis

Kata kunci

Jaringan kolaborasi para penulis

16 penulis · 61 tautan kepenulisan bersama · 22 lintas organisasi

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Udayana University
  • Universitas Bali Internasional
  • Warmadewa University
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Dewa Ayu Agus Sri LaksemiUdayana University2
Putu Ayu Asri DamayantiUdayana University2
Ni Luh RustiniUdayana University1
Putu Indah Budi ApsariWarmadewa University1
I Ketut TunasUniversitas Bali Internasional1
Luh Putu Ratna SundariUdayana University1
I Gusti Kamasan Nyoman ArijanaUdayana University1
Ni Luh AriwatiUdayana University1
Ketut TunasUniversitas Bali Internasional1
Ni Luh Putu Eka DiarthiniUdayana University1
I Kadek SwastikaUdayana University1
Ida Ayu Dewi WiryanthiniUdayana University1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OpenAlex API (jurnal SINTA, ADR 0048) https://openalex.org/S2764892910, pertama di-harvest 19 Nov 2026, terakhir terlihat 19 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"><dc:title xml:lang="en">Serum DNase1, sTNFR1 and sTNFR2 as Risk Factors for Lupus Nephritis in Systemic Lupus Erythematosus Patients</dc:title><dc:creator>Ida Ayu Ratih Wulansari Manuaba</dc:creator><dc:creator>Ketut Suryana</dc:creator><dc:creator>I Made Bakta</dc:creator><dc:creator>I Made Sudarmaja</dc:creator><dc:subject>systemic lupus erythematosus</dc:subject><dc:subject>DNase1</dc:subject><dc:subject>soluble TNF receptor 1</dc:subject><dc:subject>soluble TNF receptor 2</dc:subject><dc:subject>biomarkers</dc:subject><dc:subject>risk factors</dc:subject><dc:subject>disease progression prediction</dc:subject><dc:subject>serum biomarkers</dc:subject><dc:subject>kidney injury</dc:subject><dc:subject>TNF signaling</dc:subject><dc:subject>inflammatory markers</dc:subject><dc:subject>complement activation</dc:subject><dc:subject>autoantibodies</dc:subject><dc:subject>C5a</dc:subject><dc:subject>complement C3</dc:subject><dc:description xml:lang="en">BACKGROUND: Early detection and management of lupus nephritis (LN) in systemic lupus erythematosus (SLE) are essential to prevent irreversible kidney damage and improve patient outcomes; therefore, identifying reliable biomarkers to predict LN is paramount. However, there are still relatively few studies examining the potential biomarkers for LN in SLE patients. This study was conducted to investigate serum deoxyribonuclease I (DNase), soluble tumor necrosing factor 1 (sTNFR1) and soluble tumor necrosing factor 2 (sTNFR2) as a risk factor for LN in SLE patients.METHODS: A case-control study involving SLE patients aged 20-60 years was conducted. Blood was withdrawn from each subject for the measurement of serum level of DNase1, sTNFR1, and sTNFR2 that was performed using enzyme-linked immunoassay (ELISA) methods. Data was then analyzed using Chi-Square test and logistic regression tests.RESULTS: A total of 22 patients with LN and 22 without LN were included. The cut-off value for DNase1, sTNFR1, and sTNFR2 were 5.05 ng/mL, 6.52 ng/mL, and 7.02 ng/mL, respectively. The risk factors of LN in SLE patients were the low level of serum DNase1 (aOR=6.64; 95%CI: 1.25-35.29; p=0.026), low level of serum sTNFR1 (aOR=8.12; 95% CI: 1.56-42.10; p=0.013), and low level of serum sTNFR2 (aOR=5.57; 95%CI: 1.03-30.11; p=0.046).CONCLUSION: Serum DNase1 lower than 5.05 ng/mL, sTNFR1 lower than 6.52 ng/mL, and sTNFR2 lower than 7.02 ng/mL were risk factors for lupus nephritis in SLE patients. Hence, serum DNase1, sTNFR1 and sTNFR2 could be used as risk factors predictors for LN in SLE patients.KEYWORDS: DNase1, sTNFR1, sTNFR2, SLE, lupus nephritis</dc:description><dc:publisher>Secretariat of The Indonesian Biomedical Journal</dc:publisher><dc:date>2024-06-26</dc:date><dc:type>info:eu-repo/semantics/article</dc:type><dc:format>application/pdf</dc:format><dc:identifier>http://dx.doi.org/10.18585/inabj.v16i3.3052</dc:identifier><dc:identifier>10.18585/inabj.v16i3.3052</dc:identifier><dc:source>The Indonesian Biomedical Journal; Vol 16 No 3 (2024); 263-268</dc:source><dc:source>2085-3297</dc:source><dc:source>2355-9179</dc:source><dc:language>en</dc:language><dc:relation>https://inabj.org/index.php/ibj/article/download/3052/715</dc:relation><dc:rights>https://creativecommons.org/licenses/by-nc/4.0/</dc:rights></oai_dc:dc>